NASDAQ: AKROAkero Therapeutics Inc Stock
$20.76+0.25 (+1.22%)
Updated Apr 19, 2024
AKRO Price
$20.76
Fair Value Price
$3.96
Market Cap
$1.17B
52 Week Low
$11.25
52 Week High
$58.38
P/E
-7.18x
P/B
2.18x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$151.76M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$145M
Beta
0.86
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AKRO Overview
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKRO ($20.76) is overvalued by 424.26% relative to our estimate of its Fair Value price of $3.96 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AKRO ($20.76) is not significantly undervalued (424.26%) relative to our estimate of its Fair Value price of $3.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AKRO due diligence checks available for Premium users.
Be the first to know about important AKRO news, forecast changes, insider trades & much more!
AKRO News
Valuation
AKRO fair value
Fair Value of AKRO stock based on Discounted Cash Flow (DCF)
Price
$20.76
Fair Value
$3.96
Overvalued by
424.26%
AKRO ($20.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKRO ($20.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AKRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AKRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.18x
Industry
15.81x
Market
40.51x
AKRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.18x
Industry
5.74x
AKRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$55.2M
Profit Margin
0%
AKRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$580.3M
Liabilities
$45.0M
Debt to equity
0.08
AKRO's short-term assets ($559.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKRO's short-term assets ($559.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKRO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$48.6M
Investing
$12.8M
Financing
$502.0k
AKRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKRO vs Biotech Stocks
Akero Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.